[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tiziana Life Sciences Ltd (TLSA)

Tiziana Life Sciences Ltd (TLSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 162,892
  • Shares Outstanding, K 127,259
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,860 K
  • EBIT $ 0 M
  • EBITDA $ -16 M
  • 60-Month Beta 0.35
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 16.28

Options Overview Details

View History
  • Implied Volatility 231.27% (+53.29%)
  • Historical Volatility 71.37%
  • IV Percentile 49%
  • IV Rank 14.68%
  • IV High 1,320.09% on 09/10/25
  • IV Low 43.89% on 03/17/26
  • Expected Move (DTE 13) 0.0850 (6.34%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 16
  • Volume Avg (30-Day) 52
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 2,183
  • Open Int (30-Day) 1,843
  • Expected Range 1.2550 to 1.4250

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1400 +17.54%
on 04/13/26
1.4218 -5.75%
on 04/16/26
+0.0900 (+7.20%)
since 04/01/26
3-Month
1.1400 +17.54%
on 04/13/26
1.5700 -14.65%
on 03/02/26
-0.1700 (-11.26%)
since 01/30/26
52-Week
1.1400 +17.54%
on 04/13/26
2.6000 -48.46%
on 08/01/25
+0.0500 (+3.88%)
since 05/01/25

Most Recent Stories

More News
Aquestive Therapeutics Announces Leadership Expansion to Support Growth

Changes strategically aligned to support planned launch of Anaphylm™ (dibutepinephrine) Sublingual Film, if approved by the FDA, and to accelerate the Company’s ongoing development initiatives  ...

TLSA : 1.3400 (+4.69%)
AQST : 4.20 (+2.44%)
Tiziana Life Sciences Reports Interim Results and Expands U.S. Presence

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Tiziana Life...

TLSA : 1.3400 (+4.69%)
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

TLSA : 1.3400 (+4.69%)
AIM : 0.5153 (-0.64%)
PEPG : 1.7500 (+6.71%)
AEON : 0.8900 (-3.58%)
MBRX : 2.51 (-1.95%)
Tiziana Life Sciences Expands Phase 2 Clinical Trial for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis

Tiziana Life Sciences expands Phase 2 trial for intranasal foralumab in non-active secondary progressive multiple sclerosis across prominent Northeast institutions.Quiver AI SummaryTiziana Life Sciences,...

TLSA : 1.3400 (+4.69%)
Tiziana Life Sciences Receives ALS Association Grant to Advance Clinical Trial of Intranasal Foralumab for ALS Treatment

Tiziana Life Sciences receives funding from the ALS Association for a clinical trial of intranasal foralumab in ALS patients.Quiver AI SummaryTiziana Life Sciences, a biotechnology company focused on immunomodulation...

TLSA : 1.3400 (+4.69%)
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises

EQNX::TICKER_START (NASDAQ:TLSA),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:BIIB),(NASDAQ:TGTX) EQNX::TICKER_END

TGTX : 33.85 (+0.21%)
TLSA : 1.3400 (+4.69%)
LLY : 963.33 (+3.07%)
RHHBY : 51.0000 (+0.24%)
BIIB : 187.06 (-1.17%)
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises

TGTX : 33.85 (+0.21%)
TLSA : 1.3400 (+4.69%)
LLY : 963.33 (+3.07%)
RHHBY : 51.0000 (+0.24%)
BIIB : 187.06 (-1.17%)
Tiziana Life Sciences Appoints Matthew W. Davis, MD, RPh as Chief Medical Officer and Acting Chief Scientific Officer

NEW YORK, July 18, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling...

TLSA : 1.3400 (+4.69%)
TILS.LN : 58.500 (+8.33%)
Tiziana Life Sciences Announces Resignation of CEO

NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling...

TLSA : 1.3400 (+4.69%)
TILS.LN : 58.500 (+8.33%)
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice

NEW YORK, June 17, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling...

TLSA : 1.3400 (+4.69%)
TILS.LN : 58.500 (+8.33%)

Business Summary

Tiziana Life Sciences PLC is a biotechnology company. It focuses on the clinical development for the treatment of cancers, chronic inflammatory and autoimmune neurodegenerative disorders. The company's product pipeline consists of Foralumab TZLS-401 and Milciclib TZLS-201 which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 1.4633
2nd Resistance Point 1.4067
1st Resistance Point 1.3733
Last Price 1.3400
1st Support Level 1.2833
2nd Support Level 1.2267
3rd Support Level 1.1933

See More

52-Week High 2.6000
Fibonacci 61.8% 2.0423
Fibonacci 50% 1.8700
Fibonacci 38.2% 1.6977
Last Price 1.3400
52-Week Low 1.1400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.